Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Clinical Trial ID NCT00788957

Rank	Title	Journal	Year	PubWeight™‹?›
1	c-MET as a potential therapeutic target and biomarker in cancer.	Ther Adv Med Oncol	2011	1.81
2	Targeting the HGF/Met signaling pathway in cancer therapy.	Expert Opin Ther Targets	2012	1.45
3	EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.	Curr Mol Pharmacol	2010	1.29
4	A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.	MAbs	2011	1.14
5	Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.	Clin Cancer Res	2014	1.00
6	Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.	Eur J Cancer	2015	0.98
7	Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.	Cancer Biol Ther	2015	0.81
8	Advances in targeted and immunobased therapies for colorectal cancer in the genomic era.	Onco Targets Ther	2016	0.81
9	Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives.	Oncol Rev	2013	0.79
10	Incomplete target neutralization by the anti-cancer antibody rilotumumab.	MAbs	2016	0.78